The DOI matches its Crossref record.
Therapies for Alzheimer's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
The retina as a window to the brain—from eye research to CNS disorders
London, A., Benhar, I., & Schwartz, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.227 · Cited by 1,403
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 480
Dalby, K., Tekedereli, I., Lopez-Berestein, G., & Ozpolat, B. (2010) · Autophagy · doi:10.4161/auto.6.3.11625 · Cited by 446
The Role of Tau in Alzheimer's Disease and Related Disorders
Medeiros, R., Baglietto‐Vargas, D., & LaFerla, F. M. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00177.x · Cited by 432
RAGE regulation and signaling in inflammation and beyond
Kierdorf, K., & Fritz, G. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012519 · Cited by 428
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
Structure-Based Search for New Inhibitors of Cholinesterases
Bajda, M., Więckowska, A., Hebda, M., Guzior, N., Sotriffer, C., & Malawska, B. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14035608 · Cited by 274
Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects
Zhang, X., Li, Y., Chen, Y. E., Chen, J., & Ma, P. X. (2016) · Nature Communications · doi:10.1038/ncomms10376 · Cited by 268
Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting
Zhu, F., Qin, C., Tao, L., Liu, X., Shi, Z., Ma, X., Jia, J., Tan, Y., Cui, C., Lin, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107336108 · Cited by 255
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease
Farfara, D., Lifshitz, V., & Frenkel, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00314.x · Cited by 216
“Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd phase II clinical trial of patients with AD [137, 138].”
BackgroundDoes Alzheimer's disease begin in the brainstem?
Simic, G., Stanic, G., Mladinov, M., Jovanov‐Milosevic, N., Kostovic, I., & Hof, P. R. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01038.x · Cited by 204
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases
Barchet, T. M., & Amiji, M. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902758188 · Cited by 145
Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
Soeda, Y., Saito, M., Maeda, S., Ishida, K., Nakamura, A., Kojima, S., & Takashima, A. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181001 · Cited by 84
Shen, F., Smith, J. A. M., Chang, R., Bourdet, D. L., Tsuruda, P. R., Obedencio, G. P., & Beattie, D. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.026 · Cited by 79
Zhang, L., Lin, J., Xiang, K., Shi, T., & Guo, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.033 · Cited by 26
Adib, M., Islam, R., Ahsan, M., Rahman, A., Hossain, M., Rahman, M. M., Alshehri, S. M., Kazi, M., & Mazid, M. A. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.03.063 · Cited by 19
Li, V. O., Han, Y., Kaistha, T., Zhang, Q., Downey, J., Gozes, I., & Lam, J. C. (2024) · doi:10.1101/2024.07.06.24309990 · Cited by 8
Metadata
- Authors
- Melnikova, I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-05
- Volume
- 6
- Issue
- 5
- Pages
- 341-342
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1994693522
- Cited by
- 219
- References
- 0
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.